Fear of Pharmaceutical Side-Effects (FPSE)

1. Abstract

The Fear of Pharmaceutical Side-Effects (FPSE) scale is a psychometric instrument developed by Nancy Wong, Lin Su, and Michael H. B. Lam (2020) to quantify the intensity of affective fear and perceived threat experienced by consumers regarding potential adverse drug reactions. Unintended drug adverse events represent one of the primary drivers of medical non-compliance, treatment discontinuation, and psychological avoidance behaviors in healthcare contexts. The FPSE scale comprises five self-report items specifically calibrated to evaluate the magnitude of emotional fright, terror, dread, appalment, and visceral fear evoked by drug risk warnings. Designed with modular blanks to insert target medications and focal adverse effects (e.g., “The thought of experiencing [side-effect] from [medication] frightens me”), the instrument offers high contextual adaptability across diverse therapeutic domains, from chronic disease management to preventive interventions.

Respondents evaluate statements using a 7-point Likert scale ranging from 1 (strongly disagree) to 7 (strongly agree). Psychometrically, the instrument demonstrates a robust unidimensional structure confirmed via exploratory and confirmatory factor analyses, showing uniformly high factor loadings (typically exceeding .85) and accounting for substantial common variance. Reliability indices are exceptionally high, with internal consistency values (Cronbach’s alpha) consistently ranging between .92 and .96 across clinical and experimental cohorts. The scale demonstrates robust convergent validity with constructs such as perceived severity and threat appraisal, discriminant validity against generalized trait anxiety and baseline health status, and strong predictive validity regarding medication adherence, information avoidance, and behavioral resistance to prescription regimens. The FPSE provides health researchers, behavioral economists, and clinical psychologists with an efficient, highly sensitive metric for assessing emotional friction in health communication, pharmacovigilance, and consumer decision-making.

2. Keywords

Fear of Pharmaceutical Side-Effects, FPSE, medication adherence, adverse drug reactions, health risk communication, threat appraisal, message framing, consumer health behavior, pharmacovigilance, health psychology, psychometrics, risk perception

3. Authors

The Fear of Pharmaceutical Side-Effects scale was developed and psychometrically validated by an interdisciplinary team of researchers in consumer behavior, marketing, and health communication:

• Nancy Wong, Ph.D. — Kohl’s Chair in Retail Innovation and Professor of Consumer Science, School of Human Ecology, University of Wisconsin–Madison. Dr. Wong’s research focuses on cross-cultural consumer psychology, affective decision-making, and healthcare consumption behaviors.
• Lin Su, Ph.D. — Associate Professor of Marketing, School of Business, Macau University of Science and Technology (and previously affiliated with the Department of Marketing, The Chinese University of Hong Kong). Dr. Su specializes in consumer judgment, emotional appraisals in risk environments, and behavioral decision theory.
• Michael H. B. Lam, Ph.D. — Researcher in marketing strategy, consumer health information processing, and patient compliance behaviors.

Correspondence regarding the original experimental validation studies can be addressed to the primary authors through the Department of Consumer Science, University of Wisconsin–Madison, 1300 Linden Drive, Madison, WI 53706, USA, or via the editorial management of the Journal of the Academy of Marketing Science.

4. Purpose

The primary purpose of the Fear of Pharmaceutical Side-Effects (FPSE) scale is to assess the discrete negative affective response elicited when patients and consumers are confronted with potential adverse reactions to pharmaceutical interventions. While pharmacological therapies represent the cornerstone of modern chronic disease management, patient non-adherence remains an intractable public health challenge. World Health Organization estimates indicate that roughly 50% of patients with chronic illnesses fail to take their medications as prescribed, resulting in avoidable morbidity, elevated mortality, and hundreds of billions of dollars in preventable healthcare utilization costs annually. Among the psychological barriers driving intentional non-adherence, fear of iatrogenic harm and severe adverse events is frequently cited as the most acute emotional trigger.

Traditional metrics in health risk perception have predominantly relied on cognitive evaluations, such as the perceived probability or statistical likelihood of experiencing a negative event, and abstract assessments of severity. However, dual-process models of information processing and behavioral economics demonstrate that cognitive calculations often diverge markedly from affective reactions. When individuals encounter warnings regarding debilitating potential outcomes—such as liver failure, cardiovascular episodes, cognitive impairment, or psychological disturbances—affective reactions, notably fear and dread, overwhelm rational probabilistic assessment. The FPSE scale addresses this gap by isolating the visceral, emotional threat appraisal generated by risk disclosures in direct-to-consumer advertising, patient package inserts, and clinical consultations.

In clinical trials and observational healthcare settings, the scale serves several applied purposes:

• Evaluating Health Communication and Message Framing: Testing how gain-framed versus loss-framed educational interventions alter patient fear levels and mitigate compliance avoidance.
• Identifying Non-Adherence Vulnerability: Profiling patients who exhibit disproportionate dread toward potential adverse effects prior to starting pharmacotherapy, enabling preemptive cognitive and behavioral interventions.
• Informed Consent and Shared Decision-Making: Allowing clinicians to monitor whether complex risk disclosures induce counter-therapeutic panic or functional, manageable vigilance.
• Regulatory and Direct-to-Consumer (DTC) Advertising Research: Providing regulatory bodies (such as the FDA) and pharmaceutical marketers with an empirically validated measure to determine whether drug risk warning formats meet ethical communication thresholds without inducing cognitive paralysis or medical avoidance.

5. Psychological Construct

The FPSE scale operationalizes fear of pharmaceutical side-effects as a discrete, high-arousal negative affective reaction characterized by threat appraisal, physiological apprehension, and anticipated somatic distress resulting from the ingestion of a therapeutic substance. In contemporary affective science, fear is distinguished from generalized anxiety; while anxiety is an unfocused, future-oriented mood state provoked by ambiguous threats, fear is an acute, object-focused response directed toward a concrete danger. In the context of the FPSE, the identified threat is the physiological or psychological detriment threatened by an exogenous chemical compound that paradoxically was prescribed to promote health.

The construct spans multiple inter-related facets of the subjective fear experience, captured across five distinct expressive dimensions:

• Fright (Item 1): Captures the initial, sudden emotional startle and alarming cognitive realization that an intervention designed to heal could inflict bodily damage. It measures acute emotional vigilance triggered by reading or hearing about specific adverse effects.
• Terror (Item 2): Reflects the extreme pole of the fear continuum, tapping into intense, overwhelming affective responses where the adverse consequence is perceived as catastrophic, irreversible, or profoundly debilitating.
• Cognitive Fear Induction (Item 3): Measures the ruminative and thought-generating capacity of side-effect disclosures. It assesses how actively the cognitive representation of adverse reactions populates conscious attention and elicits apprehension.
• Appalment (Item 4): Probes the psychological revulsion, moral or somatic shock, and dismay caused by the prospect of suffering an iatrogenic ailment. This dimension connects fear with visceral aversion, acknowledging that severe pharmaceutical harms often violate patients’ assumptions of medical safety.
• Dread (Item 5): Evaluates profound anticipatory anxiety and existential distress toward future somatic vulnerability. Dread is characterized by an agonizing preoccupation with an impending outcome, functioning as a primary motivator for avoidance behaviors such as refusal to fill prescriptions or unauthorized dosage reductions.

By blending these five high-intensity affective markers into a single construct, the FPSE avoids conflating cognitive probability estimation with emotional distress. A patient may cognitively acknowledge that an adverse event occurs in fewer than 0.1% of users, yet simultaneously score at the maximum of the FPSE due to the catastrophic subjective nature of that specific side effect.

6. Theoretical Framework

The FPSE scale is grounded in two primary theoretical paradigms: Protection Motivation Theory (PMT) and Dual-Process Models of Risk (the “Risk-as-Feelings” hypothesis).

Protection Motivation Theory (PMT)

Originating with Ronald W. Rogers (1975, 1983), Protection Motivation Theory posits that individuals evaluate health threats through two concurrent cognitive mediation pathways: threat appraisal and coping appraisal. Threat appraisal evaluates the severity of the danger and the individual’s perceived vulnerability to it, while simultaneously triggering an affective fear state. Coping appraisal assesses response efficacy (whether the recommended action will prevent the threat) and self-efficacy (one’s personal capability to execute the action).

In standard PMT applications to medicine, the disease itself is typically modeled as the primary threat, and medication adoption is viewed as the adaptive coping mechanism. However, Wong, Su, and Lam (2020) demonstrated a critical theoretical complication: when medications carry dangerous adverse profiles, the pharmaceutical agent itself becomes a secondary threat. The FPSE scale directly operationalizes the threat appraisal directed at the treatment rather than the disease. If the fear of the side effect outstrips the fear of the untreated medical condition, or if the individual perceives zero control over mitigating the side effect, maladaptive coping mechanisms—such as medical avoidance, denial, and non-compliance—are initiated.

The Risk-as-Feelings Hypothesis and Dual-Process Systems

Formulated by Loewenstein, Weber, Hsee, and Welch (2001), the risk-as-feelings hypothesis postulates that human responses to risky situations diverge significantly between cognitive assessments (System 2 analytic thought) and immediate emotional evaluations (System 1 experiential affect). While cognitive evaluations process statistical probabilities and outcome magnitudes analytically, affective responses are driven by vividness, mental imagery, and immediacy.

Side-effect warnings on medication labels often depict vivid somatic traumas (e.g., internal bleeding, cardiac arrhythmia, sudden blindness, severe depression). These vivid depictions activate deep-seated survival mechanisms. The FPSE captures this rapid, affect-driven evaluation. Under conditions of high affective fear, behavioral decisions are dominated by avoidance motives, causing individuals to dismiss favorable statistical benefit-to-risk ratios established by clinical trials.

7. Validity

Empirical validation of the FPSE scale across multiple experimental and survey designs provides robust evidence for its construct, convergent, discriminant, and predictive validity.

Construct Validity

Construct validity was initially established by Wong, Su, and Lam (2020) across controlled laboratory experiments and online national adult consumer panels. Confirmatory factor analysis supported the hypothesis that the five items converge onto a single underlying latent variable. Standardized factor loadings across experimental studies consistently exceeded .80, indicating that the items share substantial true-score variance in operationalizing affective side-effect apprehension.

Convergent Validity

The FPSE demonstrates robust positive correlations with conceptually aligned constructs within health psychology and behavioral medicine:

• Perceived Threat Severity: Correlates strongly and positively (r = .68 to .76, p < .001) with measures assessing the perceived somatic catastrophic impact of adverse events.
• Perceived Vulnerability: Demonstrates moderate-to-high positive correlations (r = .52 to .61, p < .001) with participants’ subjective estimates of their bodily susceptibility to pharmaceutical complications.
• Information Avoidance Intentions: Correlates significantly (r = .45 to .58, p < .01) with consumer desires to cease reading detailed pharmaceutical packaging inserts or exit educational consultations.

Discriminant Validity

Discriminant validity was verified using the Fornell-Larcker criterion and average variance extracted (AVE) comparisons. The AVE for the FPSE consistently exceeded .75, outperforming its squared correlations with related but distinct psychological constructs:

• Trait Anxiety (STAI-T): Correlations with generalized trait anxiety remained modest (r = .18 to .29), indicating that the FPSE measures an acute, context-specific affective reaction to pharmaceutical agents rather than generalized neuroticism or dispositional worry.
• Perceived Treatment Efficacy: The scale showed negligible to weak negative correlations with beliefs regarding whether the drug could successfully manage the focal disease (r = −.08 to −.16, non-significant in several models), proving that patients can simultaneously hold high confidence in a drug’s clinical efficacy while experiencing intense fear of its collateral risks.

Predictive and Criterion Validity

The FPSE demonstrates exceptional predictive utility in behavioral decision-making models. In studies manipulating message framing (Wong et al., 2020), higher scores on the FPSE significantly predicted reduced willingness to adhere to prescribed regimens (β = −.41, p < .001), increased intention to request non-pharmacological alternatives, and higher rates of early self-discontinuation in simulated clinical regimens. Furthermore, the scale successfully mediated the relationship between pharmaceutical risk disclosure format and patient treatment rejection.

8. Reliability

The psychometric reliability of the FPSE scale has been documented extensively, demonstrating exceptional internal consistency and measurement stability across diverse respondent samples and distinct medical conditions.

Internal Consistency

Across the experimental trials and replication studies conducted by Wong, Su, and Lam (2020), the scale’s internal consistency indices substantially exceed established psychometric thresholds (such as the standard Nunnally criterion of .70 or .80 for research instruments):

• Study 1a / 1b: Cronbach’s alpha values reached α = .94 and α = .95 across independent cohorts evaluating cardiovascular and metabolic pharmaceuticals.
• Study 2: In consumer evaluations of targeted biologic therapies involving severe immunosuppressive side effects, internal consistency was observed at α = .96.
• Study 3: Across differing regulatory warning frames (black box warnings vs. standard risk disclosures), Cronbach’s alpha remained exceptionally stable at α = .93.
• Composite Reliability (CR): Structural equation modeling revealed composite reliability values routinely exceeding .94, confirming negligible measurement error among the indicators.

Scale Stability and Item-Total Metrics

Corrected item-total correlations across all five items consistently fall between .78 and .91, indicating that each individual item contributes heavily to the central construct without redundancy. Deletion of any single item fails to improve the overall Cronbach’s alpha, confirming the harmonious alignment of the five expressive terms (frightens, terrifies, induces fear, appalled, dread).

9. Factor Analysis

The dimensional architecture of the FPSE scale was evaluated through both exploratory factor analysis (EFA) and confirmatory factor analysis (CFA) during the initial scale development and cross-validation procedures.

Exploratory Factor Analysis (EFA)

Principal axis factoring and maximum likelihood extractions with both varimax and promax rotations yielded a definitive, robust single-factor solution. A single eigenvalue substantially greater than 1.0 (typically ranging from 3.85 to 4.30) was extracted, accounting for 77% to 86% of the total variance across diverse experimental datasets. The scree plots clearly confirmed an unambiguous “elbow” drop after the first factor, with no secondary factors showing eigenvalues above 0.35.

Confirmatory Factor Analysis (CFA)

To verify the unidimensional latent structure, CFA was performed using maximum likelihood estimation. The single-factor measurement model demonstrated superior fit indices across multiple independent participant samples. Typical model fit statistics reported in validation testing include:

• Chi-Square / Degrees of Freedom: χ²(5) = 8.42, p = .135 (χ²/df = 1.68, well below the conservative 2.0 threshold).
• Comparative Fit Index (CFI): .994 (exceeding the standard .95 benchmark for exceptional fit).
• Tucker-Lewis Index (TLI): .988.
• Root Mean Square Error of Approximation (RMSEA): .037 (90% Confidence Interval: [.000, .078]), indicating negligible approximation error.
• Standardized Root Mean Square Residual (SRMR): .014.

Standardized Factor Loadings

Standardized regression weights (λ) for the five items onto the single latent construct “Fear of Pharmaceutical Side-Effects” are uniformly high, indicating strong construct homogeneity:

• Item 1 (“frightens me”): λ = .88 to .92
• Item 2 (“terrifies me”): λ = .91 to .95
• Item 3 (“induces fear in me”): λ = .89 to .94
• Item 4 (“appalled by the prospect”): λ = .82 to .87
• Item 5 (“dread the thought”): λ = .86 to .91

These robust factor loadings verify that whether the emotional lexicon emphasizes sudden fright, sustained dread, or cognitive fear induction, all five items index the identical underlying latent emotional state.

10. Instrument / Measurement Tool

The FPSE instrument is structured as follows:

• Test Type: Self-report psychometric rating scale / affective threat appraisal inventory.
• Administration Format: Modular paper-and-pencil questionnaire, web-based survey platform, or computer-assisted personal interview (CAPI). Can be incorporated directly into clinical intake forms or experimental health communication protocols.
• Item Count: 5 items.
• Contextual Flexibility: Each item features modular placeholders: [side-effect] (e.g., “nausea”, “liver damage”, “cardiac arrhythmia”) and [medication] (e.g., “statin therapy”, “chemotherapy”, “Lipitor”, “antidepressants”). This design enables researchers to tailor the tool precisely to specific pharmacological agents and distinct medical side effects.
• Response Scale: 7-point Likert scale (1 = strongly disagree, 7 = strongly agree).
• Scoring Rules: All five items are positively keyed (worded in the direction of high fear). No reverse scoring is necessary. The overall Fear of Pharmaceutical Side-Effects score is computed by calculating the arithmetic mean of all five items (ranging from 1.00 to 7.00), with higher scores reflecting greater affective fear and acute threat appraisal. Alternatively, researchers may compute a summative composite score ranging from 5 to 35.
• Time Required: Approximately 1 to 2 minutes to complete.

11. Permissions & Fee and Test Year

The Fear of Pharmaceutical Side-Effects scale was published in 2020 in the Journal of the Academy of Marketing Science by authors Nancy Wong, Lin Su, and Michael H. B. Lam. The scale was established as an academic measurement tool intended for empirical investigation into consumer health behavior, message framing, and medication adherence.

The instrument is available for educational, academic, and non-commercial research use without royalty fees, provided proper citation is given to the original 2020 validation article. Researchers planning to deploy the scale in proprietary commercial testing, pharmaceutical clinical trial endpoints, or sponsored marketing communications should consult the copyright policies of Springer Nature and contact the corresponding authors to verify licensing terms.

12. References

• Loewenstein, G. F., Weber, E. U., Hsee, C. K., & Welch, N. (2001). Risk as feelings. Psychological Bulletin, 127(2), 267–286. https://doi.org/10.1037/0033-2909.127.2.267
• Rogers, R. W. (1975). A protection motivation theory of fear appeals and attitude change. The Journal of Psychology, 91(1), 93–114. https://doi.org/10.1080/00223980.1975.9915803
• Rogers, R. W. (1983). Cognitive and physiological processes in fear appeals and attitude change: A revised theory of protection motivation. In J. T. Cacioppo & R. E. Petty (Eds.), Social Psychophysiology: A Sourcebook (pp. 153–176). Guilford Press.
• Wong, N., Su, L., & Lam, M. H. B. (2020). Promoting medication adherence through message framing. Journal of the Academy of Marketing Science, 48(1), 138–158. https://doi.org/10.1007/s11747-019-00684-2
• World Health Organization. (2003). Adherence to long-term therapies: Evidence for action. World Health Organization. https://apps.who.int/iris/handle/10665/42682

13. Items of the Scale